Literature DB >> 34527562

Upregulated circRAD18 promotes tumor progression by reprogramming glucose metabolism in papillary thyroid cancer.

Wenkuan Chen1, Tingting Zhang1, Yanfang Bai1, Hong Deng1, Fang Yang2, Renjie Zhu3, Yingle Chen1, Zheng He1, Qi Zeng2, Ming Song1.   

Abstract

BACKGROUND: By regulating complex functional processes, circRNAs are crucial in the development of different cancers. Nevertheless, most circRNAs in papillary thyroid cancer metabolic reprogramming remain unknown.
METHODS: The expression of circRNA was assessed by qRT-PCR in papillary thyroid cancer tissues and cell lines. Cell proliferation and glucose intake experiments were performed by certain kit. Transwell assays and wound healing assays were performed to investigate the function of circRNA in metastasis. In addition, a serious of molecular experiments were conducted to determine the exact mechanism of circRAD18. Luciferase reporter and RNA immunoprecipitation assay were conducted to determine the molecular interaction between circRNA and miRNA.
RESULTS: We characterized circRAD18 as a significantly upregulated circRNA in papillary thyroid tissues and cell lines and found its downregulation could inhibit the growth and metastasis ability of papillary thyroid cancer. Interestingly, we found that circRAD18 was involved in glucose metabolism reprogramming of papillary thyroid cancer, and its silence could remarkably inhibit cell glucose uptake and lactate production in papillary thyroid cancer cells. Inhibition of circRAD18 could decrease the expression level of PDK1 protein by sponging miR-516b.
CONCLUSIONS: This study verified the novel function of the circRAD18-miR-516b-PDK1 axis in papillary thyroid cancer metabolic reprogramming progression, which has potential to be a novel therapeutic target. 2021 Gland Surgery. All rights reserved.

Entities:  

Keywords:  PDK1; circRAD18; circular RNAs; glucose metabolism; papillary thyroid cancer

Year:  2021        PMID: 34527562      PMCID: PMC8411097          DOI: 10.21037/gs-21-481

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  46 in total

1.  Gut Microbiota in Tumor Microenvironment: A Critical Regulator in Cancer Initiation and Development as Potential Targets for Chinese Medicine.

Authors:  Li Wang; Fu Peng; Cheng Peng; Jun-Rong Du
Journal:  Am J Chin Med       Date:  2021-03-04       Impact factor: 4.667

2.  circRAD18 sponges miR-208a/3164 to promote triple-negative breast cancer progression through regulating IGF1 and FGF2 expression.

Authors:  Yutian Zou; Shaoquan Zheng; Weikai Xiao; Xinhua Xie; Anli Yang; Guanfeng Gao; Zhenchong Xiong; Zhicheng Xue; Hailin Tang; Xiaoming Xie
Journal:  Carcinogenesis       Date:  2019-12-31       Impact factor: 4.944

3.  Circular Noncoding RNA HIPK3 Mediates Retinal Vascular Dysfunction in Diabetes Mellitus.

Authors:  Kun Shan; Chang Liu; Bai-Hui Liu; Xue Chen; Rui Dong; Xin Liu; Yang-Yang Zhang; Ban Liu; Shu-Jie Zhang; Jia-Jian Wang; Sheng-Hai Zhang; Ji-Hong Wu; Chen Zhao; Biao Yan
Journal:  Circulation       Date:  2017-08-31       Impact factor: 29.690

4.  Circular RNAs are a large class of animal RNAs with regulatory potency.

Authors:  Sebastian Memczak; Marvin Jens; Antigoni Elefsinioti; Francesca Torti; Janna Krueger; Agnieszka Rybak; Luisa Maier; Sebastian D Mackowiak; Lea H Gregersen; Mathias Munschauer; Alexander Loewer; Ulrike Ziebold; Markus Landthaler; Christine Kocks; Ferdinand le Noble; Nikolaus Rajewsky
Journal:  Nature       Date:  2013-02-27       Impact factor: 49.962

5.  Microarray is an efficient tool for circRNA profiling.

Authors:  Shasha Li; Shuaishuai Teng; Junquan Xu; Guannan Su; Yu Zhang; Jianqing Zhao; Suwei Zhang; Haiyan Wang; Wenyan Qin; Zhi John Lu; Yong Guo; Qianyong Zhu; Dong Wang
Journal:  Brief Bioinform       Date:  2019-07-19       Impact factor: 11.622

Review 6.  The chemical diversity and structure-based discovery of allosteric modulators for the PIF-pocket of protein kinase PDK1.

Authors:  Xinyuan Xu; Yingyi Chen; Qiang Fu; Duan Ni; Jian Zhang; Xiaolong Li; Shaoyong Lu
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

Review 7.  CircRNAs in cancer metabolism: a review.

Authors:  Tao Yu; Yanfen Wang; Yu Fan; Na Fang; Tongshan Wang; Tongpeng Xu; Yongqian Shu
Journal:  J Hematol Oncol       Date:  2019-09-04       Impact factor: 17.388

Review 8.  The Implications of PDK1-4 on Tumor Energy Metabolism, Aggressiveness and Therapy Resistance.

Authors:  Emine Atas; Monika Oberhuber; Lukas Kenner
Journal:  Front Oncol       Date:  2020-12-15       Impact factor: 6.244

9.  Novel Role of FBXW7 Circular RNA in Repressing Glioma Tumorigenesis.

Authors:  Yibing Yang; Xinya Gao; Maolei Zhang; Sheng Yan; Chengjun Sun; Feizhe Xiao; Nunu Huang; Xuesong Yang; Kun Zhao; Huangkai Zhou; Suyun Huang; Bo Xie; Nu Zhang
Journal:  J Natl Cancer Inst       Date:  2018-03-01       Impact factor: 11.816

10.  (-)-Sativan Inhibits Tumor Development and Regulates miR-200c/PD-L1 in Triple Negative Breast Cancer Cells.

Authors:  Fu Peng; Liang Xiong; Cheng Peng
Journal:  Front Pharmacol       Date:  2020-03-13       Impact factor: 5.810

View more
  4 in total

1.  Hsa_circ_0134111 promotes intervertebral disc degeneration via sponging miR-578.

Authors:  Peng Yan; Chong Sun; Liangrui Luan; Jialuo Han; Yang Qu; Chuanli Zhou; Derong Xu
Journal:  Cell Death Discov       Date:  2022-02-08

2.  Circular RNA KIF4A Promotes Liver Metastasis of Breast Cancer by Reprogramming Glucose Metabolism.

Authors:  Jun Huang; Xinpei Deng; Xuedong Chen; Zaoshang Chang; Quzhe Lu; Anliu Tang; Peng Liu
Journal:  J Oncol       Date:  2022-08-23       Impact factor: 4.501

Review 3.  Function and Clinical Significance of Circular RNAs in Thyroid Cancer.

Authors:  Xuelin Yao; Qiu Zhang
Journal:  Front Mol Biosci       Date:  2022-07-22

4.  CircPTPRM accelerates malignancy of papillary thyroid cancer via miR-885-5p/DNMT3A axis.

Authors:  Daping Chen; Xijiao Jiang; Huizhou Luo; Qingquan Hua; Farong Zhang
Journal:  J Clin Lab Anal       Date:  2022-09-13       Impact factor: 3.124

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.